First Bio Therapeutics announced on January 26 that it has successfully completed a Series D funding round, raising 31.7 billion KRW. This round closed above the initially planned investment amount, bringing First Bio's total cumulative funding to approximately 108 billion KRW.

First Bio Completes 31.7 Billion KRW Series D Funding Round View original image

This investment round saw participation not only from existing major investors and new financial investors, but also from strategic partners and even the company's IPO underwriter, reaffirming market confidence in First Bio's technology and growth potential. The round was led by Smilegate Investment, an existing major investor, and the newly participating Gureum Investment-Double Capital consortium, with Ligachem Bioscience, a joint development and technology transfer partner, joining as a strategic investor (SI). Additionally, Korea Investment & Securities, serving as the IPO underwriter, joined the round, officially marking the company's entry into the listing preparation phase.


Existing investors Smilegate Investment and Anda Investment Partners made follow-on investments, while Gureum Investment-Double Capital consortium, Daily Partners, Ligachem Bioscience, Mirae Asset Securities, CKD Startup Investment, Anda Asset Management, Woori Investment & Securities, Wanted Lab Partners, and Korea Investment & Securities participated as new investors.


First Bio is developing innovative new drugs, focusing on degenerative brain diseases and immuno-oncology. The company has enhanced R&D efficiency and the likelihood of success through its proprietary AI-based drug discovery platform. In particular, FB849, an HPK1 inhibitor and the company's core pipeline, is currently undergoing global Phase 1 clinical trials. Unlike existing immuno-oncology drugs, FB849 demonstrates anti-cancer effects not only through T cells but also via various immune cells, offering a differentiated mechanism of action.


Based on these research achievements and business potential, First Bio was selected as a 'pre-unicorn company' in the 2024 Global Unicorn Project organized by the Ministry of SMEs and Startups. The company is also demonstrating global-level R&D capabilities through strategic collaborations with partners such as Ligachem Bioscience, D&D Pharmatech, the Michael J. Fox Foundation (MJFF), and MSD.


With the secured funds, First Bio plans to further accelerate clinical development of its HPK1 inhibitor, while also focusing on advancing subsequent pipelines such as c-Abl and LRRK2 inhibitors. At the same time, the company will pursue technology transfer and global commercialization of its major pipelines.



Kim Jaeun, CEO of First Bio, stated, "The fact that major financial institutions and strategic partners decided to make new and follow-on investments even in a challenging environment is a testament to their confidence in First Bio's competitiveness and potential. We will work to quickly materialize partnering achievements and thoroughly prepare for an IPO to become a new drug development company with global competitiveness."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing